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Background: Several host-encoded antiviral factors suppress HIV-1 replication in a cell-autonomous fashion in vitro.
The relevance of these defenses to the control of HIV-1 in vivo remains to be elucidated. We hypothesized that
cellular restriction of HIV-1 replication plays a significant role in the observed suppression of HIV-1 in “elite
controllers”, individuals who maintain undetectable levels of viremia in the absence of antiretroviral therapy (ART).
We comprehensively compared the expression levels of 34 host restriction factors and cellular activation levels in
CD4+ T cells and sorted T cell subsets between elite controllers, HIV-1-infected (untreated) non-controllers,
ART-suppressed, and uninfected individuals.
Results: Expression of schlafen 11, a codon usage-based inhibitor of HIV-1 protein synthesis, was significantly
elevated in CD4+ T cells from elite controllers as compared to both non-controllers (p=0.048) and ART-suppressed
individuals (p=0.024), with this effect most apparent in central memory CD4+ T cells. Schlafen 11 expression levels
were comparable between controllers and uninfected individuals. Cumulative restriction factor expression was
positively correlated with CD4+ T cell activation (r2=0.597, p<0.0001), viral load (r2=0.34, p=0.015), and expression of
ISG15 (r2=0.73, p<0.0001), a marker of interferon exposure. APOBEC3C, APOBEC3D, CTR9, TRIM26, and TRIM32 were
elevated in elite controllers with respect to ART-suppressed individuals, while levels were comparable to uninfected
individuals and non-controllers.
Conclusions: Host restriction factor expression typically scales with cellular activation levels. However, the elevated
mRNA and protein expression of schlafen 11, despite low activation and viral load, violates the global pattern and
may be a signature characteristic of HIV-1 elite control.
Keywords: Elite controllers, Intrinsic immunity, Retroviral restriction factors, APOBEC3, BST2/tetherin, TRIM, schlafen
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To date, there is no effective cure or prophylactic vaccine
for HIV-1 infection. Antiretroviral therapy (ART) has dra-
matically decreased the morbidity and mortality associated
with HIV-1 infection. However, there is a demand for alter-
native clinical management strategies due to the necessity
of lifelong therapy, evolution of antiretroviral resistance,
toxicity issues, and substantial costs of current regimens
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distribution, and reproduction in any mediumundetectable levels in the absence of ART, and therefore
represent a promising model for a functional cure. The im-
munological determinants of control in these individuals
may serve as foundations for novel antiretroviral strategies.
HIV-1 elite controllers appear to be a heterogeneous
group, and the observed suppression of HIV-1 in these in-
dividuals has been attributed to a number of virologic, im-
munologic and genetic characteristics [2,3]. Although there
are indications that viruses in elite controllers may be less
virulent than strains in non-controllers [4], HIV-1 isolates
from controllers often exhibit typical replication kinetics
in vitro suggesting that reduced viral fitness cannot fully ex-
plain this phenomenon [5]. Multiple studies suggest thatCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and exhibit high functionality and proliferative capacity in
elite controllers. Elite controllers have higher CD8+ T cell
activation levels than ART-suppressed individuals, despite
maintaining clinically undetectable levels of viral replication
and lower CD4+ T cell activation levels [8]. Certain human
leukocyte antigen (HLA) class I alleles such as HLA-B*57
and HLA-B*27 are overrepresented in elite controllers, and
the protective effects of these alleles are thought to be
CD8+ cell-mediated. However, not all elite controllers have
protective HLA alleles [9], and some individuals with
established protective alleles progress to disease rapidly
[10]. CD8+ T cell responses alone cannot explain the elite
controller phenotype, and other immunologic and molecu-
lar mechanisms likely play a role [9].
In addition to adaptive immune responses against
HIV-1, cell-intrinsic mechanisms may play an important
role in mediating resistance to HIV-1 infection in elite
controllers. Genome wide mRNA expression studies
suggest that a transcriptional profile signature of CD4+
T cells is associated with HIV-1 elite control and viral
set point in viremic individuals [11,12]. In support of tar-
get cell-associated signature characteristics, CD4+ T cells
from elite controllers may exhibit decreased susceptibil-
ity to HIV-1 infection ex vivo as compared to cells from
viremic individuals, and cellular susceptibility to HIV-1
in controllers is predictive of reservoir size (total cell-
associated HIV-1 DNA levels) [13,14]. However, this ob-
servation is controversial, and other studies report
conflicting results [15-17]. Cell-intrinsic factors that
contribute to HIV-1 control may include a number of
recently identified proteins that restrict HIV-1 replica-
tion in target cells, and provide the host with a pre-
mobilized defense against retroviral infection. The most
widely recognized restriction factors are TRIM5α [18],
APOBEC3G [19], and BST2/tetherin [20,21], and a num-
ber of additional factors with anti-HIV-1 activity have
been identified and characterized in recent years. Our
group recently published data suggesting that the BST-2
/tetherin restriction factor plays a critical role in the
interferon-mediated suppression of HIV-1 viremia in
chronically infected individuals [22]. Although a few re-
ports have examined the relevance of single factors (e.g.
APOBEC3G) to HIV-1 plasma viral load and elite con-
trol [23], the overall contribution of host restriction
mechanisms to HIV-1 elite control remains to be
elucidated [2].
To address the hypothesis that cellular restriction of
HIV-1 replication plays a significant role in the observed
suppression of HIV-1 in elite controllers, we comprehen-
sively compared restriction factor expression patterns and
cellular activation levels in CD4+ T cells and T cell subsets
between elite controllers, HIV-1-infected (untreated) non-
controllers, ART-suppressed, and uninfected individualsenrolled in the UCSF SCOPE cohort. Restriction mecha-
nisms suppress HIV-1 replication, while target cell activa-
tion promotes HIV-1 transactivation, replication, and
production [24,25]; therefore, consideration of these two
parameters in a synchronous fashion will allow us to gauge
overall cell-intrinsic susceptibility to HIV-1 infection. We
designed and implemented a custom TaqMan Low Density
Array (TLDA) to measure the expression of 34 anti-HIV-1
restriction genes. The precise prerequisites for achieving
the designation of host restriction factor are somewhat con-
troversial. Moreover, this repertoire is by definition a mov-
ing target as new restriction mechanisms come to light. We
relied on the following two minimal criteria for inclusion in
our “Cumulative Restriction” or “CuRe” TLDA: 1) Peer-
reviewed, published evidence of direct inhibition of HIV-1
replication in vitro, and 2) Detectable expression in human
peripheral blood mononuclear cells. In addition to bona
fide, extensively characterized restriction factors such as
APOBEC3G and BST-2/tetherin, the CuRe array measures
a number of recently identified candidate anti-HIV-1 re-
striction factors to maximize the breadth, impact and
generalizability of our translational study. Some of these
factors may play functional roles outside of antiretroviral
defense, and as of yet, co-evolutionary studies revealing ca-
nonical signatures indicative of historical host-pathogen
conflict have not been performed across all sampled gene
targets. However, all factors in the CuRe array meet the es-
sential, minimal definition of a host restriction factor, and
function in a cell-autonomous manner to suppress HIV-1
replication.
In addition to considering the individual expression of
34 anti-HIV-1 restriction genes, we created an intuitive
mathematical construct to represent the overall, cumula-
tive anti-HIV-1 restriction capacity associated with each
sample. This metric, or “CuRe score”, captures the cu-
mulative fold-difference in antiviral gene expression with
respect to a control individual.
Results
Schlafen 11 expression is elevated in elite controllers
We implemented the “CuRe” (Cumulative Restriction)
TLDA to measure the mRNA expression of 34 anti-HIV-1
genes in CD4+ Tcells from 48 subjects equally representing
four HIV-1 disease states (12 elite controllers, 12 non-
controllers, 12 ART-suppressed, and 12 HIV-1-uninfected
individuals). The complete list of surveyed genes along with
their respective reported anti-HIV-1 roles is presented in
Table 1, precise disease state definitions are described in
Table 2, and individual subject characteristics are docu-
mented in Additional file 1: Table S1. To represent overall
HIV-1 inhibitory potential, we defined the CuRe score as
the cumulative fold-difference in restriction factor expres-
sion with respect to a control individual (described in
greater detail in the Methods section).
Table 1 List of the 34 anti-HIV-1 host restriction factors measured by our CuRe array
Name NCBI ENTREZ gene description Key anti-HIV-1 role(S) REFS
APOBEC3
(A-H)
Apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like3
Hypermutation; lethal mutations in viral DNA; Inhibition of reverse




Tripartite motif family Targeting of viral capsid; Inhibition of viral transcription [18,34–36]
BST2/tetherin Bone marrow stromal cell antigen 2 Blocks release of enveloped viruses [20,21]
CDKN1A
(P21)
Cyclin-dependent kinase inhibitor 1A (p21,
Cip1)
Blocks reverse transcription; Blocks RNA transcription by reducing activity
of CDK9
[13,37,38]
PAF1 Paf1, RNA polymerase II associated factor Inhibits early events of viral life cycle from reverse transcription to
integration
[39]
CTR9 Ctr9, Paf1/RNA polymerase II complex
component
Inhibits early events of viral life cycle from reverse transcription to
integration
[39]
RTF1 Rtf1, Paf1/RNA polymerase II complex
component
Inhibits early events of viral life cycle from reverse transcription to
integration
[39]
EIF2AK2 (PKR) Eukaryotic translation initiation factor 2-alpha
kinase 2
Inhibits viral protein translation by protein phosphorylation; promotes
innate immune signaling
[40]
HERC5 HECT domain and RLD 5 Blocks early stage of retroviral particle assembly [41]
IFITM Family
(3 members)
Interferon induced transmembrane protein Inhibits cytosolic entry [42]
ISG15 ISG15 ubiquitin-like modifier Blocks interaction between HIV-1 Gag and Tsg101 (ESCRT-I) required for
efficient budding of HIV-1
[43]
MOV10 Mov10, Moloney leukemia virus 10, homolog Inhibits proteolytic processing of Gag and reverse transcription [44]
RNASEL Ribonuclease L (2',5'-oligoisoadenylate
synthetase-dependent)





Radical S-adenosyl methionine domain
containing 2
Inhibits viral production [46]
SAMHD1 SAM domain and HD domain 1 Inhibits HIV replication in myeloid cells, probably by regulating cellular
dNTP supply
[47]
SLFN11 Schlafen family member 11 Inhibits viral protein synthesis [48]
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peripheral tissues, and therefore gene expression in this cel-
lular subset is likely to be most relevant to viral production
and propagation. CD4+ T cells were negatively-selected
from freshly-collected blood with near 100% purity as de-
scribed previously [22]. Expression of anti-HIV-1 genes in
CD4+ T cells, as summarized by the CuRe score, was sig-
nificantly higher in non-controllers as compared to elite
controllers (p=0.007), ART-suppressed (p=0.002), or unin-
fected controls (p=0.003) (Figure 1). A complete list of rela-
tive copy numbers for each restriction factor, and p-values
for all inter-disease state gene expression comparisons are
presented in Table 3 and Additional file 1: Table S2, re-
spectively. These data suggest that overall, global restriction
factor expression is not enhanced in elite controllers with
respect to other HIV-1 disease groups, in contrast to the
near-global induction of antiviral restriction mechanisms
observed in individuals undergoing interferon-α therapy
(unpublished observations, M. Abdel-Mohsen et al.).
Although CuRe scores and the majority of individual
gene-specific mRNA measurements were highest in
viremic non-controllers with respect to other groupsrepresented in our study (Figure 1), we sought to deter-
mine if particular anti-HIV-1 restriction factors violated
this average behavior and exhibited high mRNA expres-
sion levels in HIV-1 elite controllers. We performed it-
erative univariate analyses to identify genes that were
maximally expressed in elite controllers with respect to
other HIV-1-infected individuals. Our analyses revealed
that a single factor, schlafen 11, was expressed at a sig-
nificantly higher level in CD4+ T cells from elite control-
lers with respect to viremic, untreated non-controllers
(p=0.048) and ART-suppressed (p=0.024) individuals
(Figure 2A). Schlafen 11 is a recently identified anti-
HIV-1 restriction factor that potently suppresses HIV-1
replication by codon usage-based inhibition of HIV-1
protein synthesis [48].
We next performed an exploratory analysis of the
mRNA expression of schlafen 11 in central memory and
effector memory CD4+ T cell subsets. Multiple reports
suggest that elite controllers and long-term non-
progressors harbor higher relative numbers of central
memory CD4+ T cells, and these cells exhibit distinct
phenotypic properties from viremic non-controllers
Table 2 Definitions of HIV-1 disease states
Patient category Definition
Elite Controllers Antiretroviral therapy-naïve subjects who have at
least one year duration of documented viral loads
that are below the level of detection of
conventional assays up until the date of specimen
acquisition.
Non-controllers Subjects who have had at least one documented
viral load above 10,000 copies/ml who are not
taking antiretroviral therapy.
ART Suppressed Subjects taking antiretroviral therapy who have had
at least three months duration of documented viral
loads that are below the level of detection on
conventional assays.
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and effector memory populations in a subset of 20 indi-
viduals (5 of each disease state), and the CuRe array was
implemented to measure restriction gene expression.
Our data from these cellular subsets reveal that central
memory CD4+ T cells from elite controllers (Figure 2B),
but not effector memory cells (Figure 2C), express sig-
nificantly higher levels of schlafen 11 (p=0.031) than cor-
responding cellular subsets from viremic non-controllers
(although a trend was apparent in effector memory
cells).
To confirm that our schlafen 11 mRNA expression
data were recapitulated at the protein level, we measured
schlafen 11 protein expression in CD4+ T cells from a
subset of four elite controllers and four non-controllers,
chosen based on range of mRNA expression and avail-
ability of remaining specimens (data points in Figure 2A
corresponding to samples chosen for subsequent protein
characterization are highlighted with black bordering).
Our western blots demonstrate that schlafen 11 protein
expression (normalized to GAPDH protein level to con-
trol for loading) is elevated in elite controllers withFigure 1 Relationship between restriction factor expression and HIV-1
disease states. Reported p-values were obtained using unpaired t tests. (B)
across HIV-1 disease states. Fold-differences of each gene’s expression leve
control group are reported. Yellow coloring indicates value of 1 (expression
coloring indicates elevated relative expression, and green coloring indicate
single individual.respect to non-controllers, validating our mRNA-based
observations (Figure 2D). Moreover, schlafen 11 normal-
ized protein levels and mRNA relative copy numbers ex-
hibit a near-perfect correlation, suggesting that mRNA
quantitation is a reliable strategy for measuring schlafen
11 expression in primary cells (Figure 2E).
Restriction factor expression in vivo is correlated with
CD4+ T cell activation
Based on our observation that restriction factor expres-
sion was highest in non-controllers, we hypothesized
that restriction gene expression fluctuates in tandem
with CD4+ T cell activation levels. We used flow cytom-
etry to determine the relative levels of CD4+ T cell acti-
vation in all study subjects. T cell activation levels were
reported as a percentage of CD4+ T cells co-expressing
HLA-DR and CD38, as well as the mean fluorescence
intensity (MFI) of HLA-DR. In our study population,
non-controllers had a higher frequency of activated
CD4+ T cells compared to elite controllers (p<0.0001),
ART-suppressed (p=0.003), or uninfected individuals
(p<0.0001) (Figure 3, Figure 4A). We additionally ob-
served a higher frequency of activated CD4+ T cells in
the ART-suppressed group compared to elite contro-
llers (p=0.033) and uninfected individuals (p<0.015)
(Figure 4A). The CD4+ activation profiles reported here
recapitulate previously reported data [8]. Focusing on all
HIV-1 infected, untreated individuals, we identified sta-
tistically significant correlations between the CuRe score
and frequency of activated CD4+ T cells (r2=0.597,
p<0.0001) (Figure 4B), and HIV-1 plasma viral load
(r2=0.336, p=0.015) (Figure 4C). We also examined the
relationship between the CuRe score and the expression
of interferon-stimulated gene 15 (ISG15), a marker of
interferon exposure, and observed a strong correlation
(r2=0.73, p<0.0001) (Figure 4D).disease state. (A) CuRe (Cumulative Restriction) scores across HIV-1
Heat map representing expression of individual restriction genes
l in relation to the median values for each gene in the HIV-negative
values equivalent to the median of HIV-negative controls). Red
s suppressed relative expression. Each column represents a
Table 3 Anti-HIV-1 restriction factor mRNA relative copy number1
HIV negative controls Elite controllers ART-suppressed Non-controllers
APOBEC3A 9.45 ± 2.3 7.95 ± 3.2 7.25 ± 1.6 10.23 ± 2.9
APOBEC3B 2.76 ± 0.5 3.230.8 4.91 ± 1.2 11.65 ± 2.7
APOBEC3C 419.62 ± 42.3 509.99 ± 38.9 393.1 ± 27.1 545.81 ± 49.5
APOBEC3D 96.42 ± 12.4 125.44 ± 11.2 92.44 ± 8.7 139.17 ± 14
APOBEC3F 2 ± 0.3 2.73 ± 0.4 1.88 ± 0.2 3.35 ± 0.4
APOBEC3G 66.29 ± 9 87.22 ± 7.4 67.16 ± 6.6 84.02 ± 9.7
APOBEC3H 10.88 ± 2.2 12.89 ± 2.6 12.53 ± 1.6 16.74 ± 3
BST2 59.15 ± 9.1 81.19 ± 9.9 62.31 ± 8.5 108.6 ± 16.5
CDKN1A (P21) 90.75 ± 25.8 74.43 ± 41.1 77.39 ± 29.9 48.6 ± 11.5
CTR9 170.92 ± 11 175.81 ± 11.1 146.7 ± 5.6 164.3 ± 8.1
EIF2AK2 416.56 ± 11.8 359.92 ± 14.5 434.52 ± 11.5 805.28 ± 8.1
HERC5 179.53 ± 28.7 129.72 ± 9.1 146.37 ± 22.2 250.33 ± 20.9
IFITM1 12102.96 ± 624.2 13852.2 ± 778 11789.6 ± 1190 18163.4 ± 1222.4
IFITM2 2325.19 ± 161.3 2442.24 ± 178 2256.65 ± 195.9 2903.74 ± 239.8
IFITM3 66.43 ± 17.1 85.81 ± 13.6 97.44 ± 16 143.82 ± 20.9
ISG15 17.85 ± 3.7 16.82 ± 2.3 26.91 ± 8.3 56.58 ± 9.1
MOV10 151.25 ± 10.6 162.57 ± 14.7 137.56 ± 10.6 190.16 ± 9.9
PAF1 95.25 ± 3.6 98.88 ± 6.4 87.55 ± 4.2 102.38 ± 6.4
RNASEL 34.34 ± 2.9 37.96 ± 3.5 31.75 ± 2.9 34.32 ± 2.5
RSAD2 (Viperin) 29.86 ± 12.8 23.2 ± 2.5 37.11 ± 11.2 102.81 ± 15.4
RTF1 322.64 ± 18.2 323.08 ± 24.1 276.97 ± 16.5 322.93 ± 15.7
SAMHD1 1322.37 ± 159.4 1420.63 ± 95.8 1470.53 ± 78 1685.26 ± 92.4
SLFN11 92.4 ± 10.1 80.98 ± 10.3 54.64 ± 3.4 57.44 ± 4.6
TRIM11 85.09 ± 7.4 82.25 ± 6.3 72.81 ± 6.4 97.63 ± 10.1
TRIM14 296.58 ± 25.6 351.14 ± 26.8 302.04 ± 24 460.72 ± 42.5
TRIM19 (PML) 180.3 ± 14.5 203.55 ± 16.1 169.58 ± 13 267.52 ± 27.6
TRIM21 128.44 ± 8.9 133.74 ± 8.6 120.86 ± 10.3 148.63 ± 11.1
TRIM22 1547.88 ± 124.4 1457.21 ± 93.4 1418.98 ± 78.9 2049.2 ± 89.4
TRIM26 197.14 ± 16.2 188.7 ± 13.3 146.16 ± 14 201.34 ± 18.4
TRIM28 545.06 ± 27 562.97 ± 36.6 499.71 ± 32.2 527.79 ± 28.5
TRIM32 178.17 ± 12.7 173.69 ± 14 139.87 ± 7.3 180.89 ± 16.9
TRIM5 68.18 ± 10.6 86.44 ± 7.2 77.97 ± 5.7 108.67 ± 6.8
1Mean ± standard error.
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expression profile from ART-suppressed individuals
As HIV-1 replication apparently drives expression of many
restriction factors, we compared gene expression in the two
“aviremic” infected groups (controllers and ART-suppressed).
Our rationale was that differences in gene expression be-
tween these groups would be minimally confounded by dif-
ferences in HIV-1 antigen levels, and may provide insights
into factors which are mechanistically associated with virus
control. In this two-way comparison, five anti-HIV-1 restric-
tion genes were significantly elevated in elite controllers
when compared to ART-suppressed subjects: APOBEC3C
(p=0.022), APOBEC3D (p=0.029), CTR9 (p=0.028), TRIM26(p=0.038), and TRIM32 (p=0.044) (Figure 5A-E). No genes
were elevated in ART-suppressed individuals with respect to
controllers. The enhanced expression of these five genes in
elite controllers violates the typical positive correlation with
CD4+ T cell activation, as does schlafen 11. We examined
the correlations between the expression of restriction genes
and CD4+ T cell activation within the two aviremic, HIV-1-
infected groups. CDKN1A/p21 was the only gene that
exhibited a significant correlation in elite controllers; its ex-
pression was positively correlated with activation in control-
lers (r2=0.42, p<0.023) (Figure 5F), while there were no
significant correlations between gene expression and activa-
tion in ART-suppressed individuals.
Figure 2 Elevated expression of schlafen 11 in HIV-1 elite controllers. (A) schlafen 11 (SLFN11) expression in unfractionated CD4+ T cells
across disease states. Data points involved in subsequent protein characterization are highlighted with black bordering. (B) SLFN11 expression in
central memory CD4+ T cells. (C) SLFN11 expression in effector memory CD4+ T cells. Reported p-values in panels A-C were obtained using
unpaired t tests. (D) SLFN11 protein expression in elite controllers and non-controllers, as determined by western blot. Immunoblotting bands
were quantified with ImageJ64 software. The quantified SLFN11 protein expression levels were normalized to corresponding GAPDH protein
levels to ensure equal loading. (E) Correlation between SLFN11 normalized protein level and mRNA relative copy number. A Spearman’s rank test
was used to evaluate the significance of the correlation.
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Our overall objective was to determine the relevance of
host-encoded anti-HIV-1 restriction factors to HIV-1
elite controller status. We measured the relative expres-
sion levels of 34 different antiviral factors in CD4+ T
cells from elite controllers to ascertain if one or more re-
striction genes are associated with the control of HIV-1
in vivo. Overall restriction factor expression (as mea-
sured by the CuRe score) exhibited significant, pro-
nounced relationships with T cell activation and ISG15
expression (an indicator of interferon levels), and a less
pronounced positive correlation with viral load. This
pattern likely reflects a scenario in which restriction fac-
tor expression is primarily driven by cellular activation
and interferon exposure in vivo, mirroring recent data
from our group derived from in vitro experiments [51]
and studies of HLA-B*57-positive healthy donors [52].
The moderate correlation with viral load likely reflects
an indirect association (since activation and interferonexpression are driven by viral antigen). This pattern par-
allels data describing positive correlations between the
breadth and magnitude of anti-HIV-1 CD8+ responses
and viral load observed in structured treatment interrup-
tion studies [53]. Natural variation in restriction factor
mRNA expression on a global level, considered inde-
pendently of other cellular and immunologic parameters,
does not appear to be a prognostic indicator of effective
viral control in vivo. However, overall restriction factor
expression may serve as a prognostic indicator of HIV-1
suppression within the context of exogenous interferon-
α treatment, when expression and activity of several fac-
tors is induced to supraphysiologic levels (unpublished
observations, M. Abdel-Mohsen et al.).
Schlafen 11 [48] was the only gene in our array that
exhibited significantly higher expression in elite control-
lers as compared to both viremic non-controllers and
ART-suppressed groups. This suggests that schlafen 11
may play a role in the suppression of HIV-1 in vivo, by
Figure 3 Frequency of activated CD4+ T cells across HIV-1 disease states. CD38 and HLA-DR expression on the surface of CD4+ T cells was
measured by flow cytometry. Plots for three representative, median individuals are included for each HIV-1 disease state. Percentages of activated
cells (co-expressing CD38 and HLA-DR) are reported in the upper-right quadrant of each plot.
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tRNA limitation and codon-based discrimination (HIV-1
favors A/T-rich codons in reflection of its skewed base
composition). Moreover, expression data from our ex-
ploratory analyses of sorted T cell subsets indicate that
schlafen 11 may specifically contribute to the distinct
phenotypic signature and resilience associated with
CD4+ central memory cells from HIV-1 elite controllers
[49,50]. However, despite the fact that we were able toidentify statistically significant differences in expression
levels between patient groups in these subsets that reca-
pitulated the hierarchy observed in unsorted CD4+ cells,
these observations warrant validation using larger sam-
ple sizes.
The hierarchy of schlafen 11 gene expression violates the
typical linkage with cellular activation levels and interferon
exposure. In addition, the lack of a significant difference
between uninfected individuals and elite controllers in
Figure 4 Immunologic and virologic correlates of host restriction factor expression. (A) Frequency of activated (CD38+ HLA-DR+) CD4+ T
cells across disease states. Reported p-values were obtained using unpaired t tests. Correlations between CuRe score and CD4+ T cell activation,
HIV-1 viral load, and ISG15 expression in HIV-1-infected, untreated individuals (elite controllers and non-controllers) are reported in (B), (C), and
(D), respectively. Correlations were evaluated using Pearson’s r tests.
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viremic non-controllers and ART-suppressed HIV-1-
infected individuals suggests that controllers may be
protected from viral downregulation of the schlafen 11 fac-
tor. This pattern may be driven by host and/or viral deter-
minants; elite controllers may harbor a genetic variant of
the schlafen 11 protein that is less susceptible to HIV-1 eva-
sion and modulation. Alternatively, elite controllers may be
infected by genetic variants of HIV-1 that exhibit attenuated
capacity to downregulate schlafen 11, mirroring reported
observations that HIV-1 strains in elite controllers express
weak or defective versions of the Nef and Vif proteins [4].
However, as of yet, this is speculative, since a schlafen 11
antagonistic factor in HIV-1 remains to be identified. An-
other possibility stems from the characteristics of unin-
fected controls included in our study; this population,
reflecting the composition of uninfected individuals en-
rolled in the SCOPE cohort, is enriched for highly HIV-
exposed seronegative individuals, and factors such as
schlafen 11 that contribute to viral control may also protect
against HIV-1 acquisition. This is supported by the observa-
tion that amongst uninfected controls in our study, highly-exposed individuals express schlafen 11 at significantly
higher levels than individuals with minimal exposure (data
not shown).
It is important to note that despite statistically significant
differences between patient groups, not all elite controllers
in our study expressed schlafen 11 at elevated levels. Some
controllers exhibit high schlafen 11 mRNA and protein ex-
pression, while other controllers are indistinguishable from
non-controllers. This pattern mirrors other immunologic
measurements of elite controllers; these individuals exhibit
highly heterogeneous neutralizing antibody responses and T
cell phenotypes [2,3,54]. This variability may reflect a sce-
nario whereby some elite controllers are immunologically
adapted to retroviral infection, while others simply maintain
undetectable viremia due to poor replicative fitness of the
infecting viral strain.
Five restriction factors (APOBEC3C, APOBEC3D,
TRIM26, TRIM32, and CTR9) were elevated in elites when
compared specifically to ART-suppressed individuals, who
have similar levels of residual viremia. The elevated expres-
sion of these five genes, including APOBEC3 cytidine deam-
inases and TRIM-family members, constitutes an elite
Figure 5 Elevated expression of restriction factor genes in HIV-1 elite controllers with respect to ART-suppressed individuals. Five
restriction factors were significantly elevated in elite controllers with respect to ART-suppressed subjects: (A) APOBEC3C, (B) APOBEC3D, (C) CTR9,
(D) TRIM26, and (E) TRIM32. Gene expression between groups was compared using unpaired t tests. (F) The expression of CDKN1A/p21 was
positively correlated with CD4+ T cell activation in elite controllers. There were no correlations between gene expression and activation in
ART-suppressed individuals. Correlations were evaluated using Pearson’s r tests.
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CDKN1A/p21 scales with CD4+ T cell activation in elites
(while no such correlations were observed in treated pa-
tients). CDKN1A/p21, a potent inhibitor of cyclin-
dependent kinases, has recently been proposed to exert
in vivo anti-HIV-1 activity, and is believed to be
overexpressed in CD4+ T cells from elite controllers [13].
However, other groups report that CDKN1A/p21 is not dir-
ectly involved in HIV-1 restriction [14]. We found no statis-
tically significant difference in the expression levels of
CDKN1A/p21 in elite controllers compared to any of the
other three disease states. This observation remained con-
sistent when the mRNA expression of these factors was ex-
amined specifically in central memory and effector memory
CD4+ T cell subsets. The observation that expression of p21
was significantly correlated with CD4+ T cell activation in
controllers, but not in any of the other groups included in
our study, is provocative. This suggests that the inducibility
and responsiveness of this defense factor to viral antigen, ra-
ther than constitutive overexpression, may contribute to the
elite controller phenotype.There are certain caveats associated with these data
and their interpretation. Unlike studies involving in vitro
or animal models, it is difficult to unequivocally demon-
strate a causal relationship between restriction factor ex-
pression and the control of HIV-1 using a patient-based
study design. Consideration of our findings within the
context of the robust literature describing a causal rela-
tionship between these restriction factors and HIV-1
suppression in vitro (Table 1) lends credibility to these
in vivo observations. Another caveat involves our
characterization of mRNA expression levels. Although
concordance between mRNA and protein expression has
been demonstrated for several of our studied factors,
mRNA may not always accurately predict protein con-
centrations. Although we performed confirmatory pro-
tein quantitation to validate elevated schlafen 11
expression in elite controllers, cellular protein concen-
trations may not always accurately reflect antiviral activ-
ity in vivo. Functional assays using clinical specimens
from elite controllers will complement and extend these
findings.
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Our data suggest that overall restriction factor gene expres-
sion, captured in our CuRe score, is highest amongst non-
controllers, likely a reflection of increased viral antigen and
interferon exposure. However, the codon-usage-based in-
hibitor of HIV protein synthesis schlafen 11 is a notable ex-
ception to this pattern. Elevated schlafen 11 expression is a
signature characteristic of HIV-1 elite control and may play
a role in the suppression of HIV-1 in vivo. These findings
complement earlier reports suggesting that CD4+ T cells
from controllers are refractory to HIV-1 infection ex vivo.
Continued investigation into the regulation, tissue-specific
expression, and antiretroviral capacity of host restriction fac-
tors will likely benefit the development of therapeutic and
curative strategies for HIV-1 infection.Methods
Subjects and specimen processing
60 cc of blood was collected prospectively from 48
individuals enrolled in the UCSF SCOPE Cohort. The
research was approved by the relevant institutional
review boards, and all human participants gave writ-
ten informed consent. Disease state definitions are
described in Table 2, and individual subject character-
istics are documented in detail in Additional file1:
Table S1. Plasma RNA viral load and CD4+ T cell
counts were measured at all patient visits. Total blood
from all subjects was processed with Ficoll-Plaque
PLUS and 106 PBMCs were immediately subject to
CD4+ cell enrichment. CD4+ T cells were enriched
from fresh PBMCs using the EasySep Human CD4+
T Cell enrichment magnetic kit (StemCell Technolo-
gies), according to the manufacturer’s instructions.
Total RNA extraction was performed directly after
enrichment.Cell sorting
A subset of 20 individuals (5 of each disease status) were
chosen for sorting; four CD4+ T cell subpopulations
(naïve, central memory, transitional memory, and effector
memory cells) were isolated using a FACS-based sorting
procedure. PBMCs were isolated by Ficoll density gradi-
ent, stained with aqua amine reactive dye, and then
stained with fluorescently conjugated monoclonal anti-
bodies against CD3, CD4, CD45RO, CD27, CCR7, CD57
and CD14. After gaining on lymphocytes and singlets, and
excluding non-viable cells (using the amine reactive dye)
and CD14+ monocytes, CD3+CD4+ cells were sorted as
follows: [1] Naïve (CD45RO-CCR7+CD27+CD57-); [2]
Central Memory (CD45RO+CCR7+CD27+); [3] Tran-
sitional Memory (CD45RO+CCR7-CD27+); and [4]
Effector Memory (CD45RO+CCR7-CD27-) (Additional
file 1: Figure S1).Gene expression profiling
Total RNA was extracted from enriched CD4+ T cells
using 700 μl of Qiazol reagent (Qiagen), followed by 15
min centrifugation at 12,000 g at 4°C. RNA was
extracted from the aqueous layer using the miRNeasy
Mini kit (Qiagen) with on-column DNAase treatment
(Qiagen RNase-Free DNase Set) and eluted in 30 μl of
RNase-free water. DNase-treated, clean RNA was tran-
scribed into cDNA using random primers and the
SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen),
according to manufacturer’s instructions. Quantitative
real-time PCR utilized custom-made TaqMan® Low
Density Arrays (TLDA) from Applied Biosystems follow-
ing the manufacturer’s instructions. TaqMan Low Dens-
ity Array (TLDA) cards (Applied Biosystems, Foster
City, CA) are 384-well microfluidic cards with eight
ports, each containing 48 connected wells. The primers
and probes for each assay were preloaded and dried onto
the designated duplicate wells. All probes used on our
card are conjugated to 6-carboxyfluorescein (FAM).
Black hole quencher 1 (BHQ1) was used as a quencher
for all probes. The Cumulative Restriction (CuRe) TLDA
card is designed to run 4 samples in duplicate on one
card. Each port tests against 34 different antiviral genes
and a panel of housekeeping genes. All assays and their
respective target genes are listed in Table 1. Thermal
cycling was performed using an ABI ViiA™ 7 Real-Time
PCR System. Up to 450 ng cDNA in 200 μl of Applied
Biosystems TaqMan Universal PCR Master Mix with
UNG was loaded onto the designated ports of the TLDA
plates. Data was analyzed using ABI ViiA™ 7 software. A
panel of 6 housekeeping genes was included in the
TLDA plates (GAPDH, 18S, ACTB, PPIA, RPLP0, and
UBC). RPLP0 was identified as the most stably expressed
gene from those 6 housekeeping genes among all sam-
ples using the GeNorm algorithm [55]. Therefore, raw
cycle threshold numbers of amplified gene products
were normalized to the housekeeping gene, RPLP0, (60S
acidic ribosomal protein P0) to control for cDNA input
amounts. Fold induction was determined using the com-
parative Ct method [55].
CuRe score calculation
The expression value for the ith gene is notated as ei,
i=1,2,…,n, assuming there are n genes. Missing values
were imputed using the minimum expression value
across samples for each gene, respectively. The median
gene expression profile is calculated for the HIV-1-
uninfected control group. A reference sample with the
maximum number of genes that are closest to the me-
dian gene expression profile is the chosen from the un-
infected control group. The reference expression value
for the ith gene is notated as ri, i=1,2,…,n. The gene ex-
pression profile for each sample was standardized by
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CuRe score for a sample is the cumulative fold-
difference in antiviral gene expression with respect to a





Eight cryopreserved PBMC samples (four elite controller,
four non-controller) were chosen for protein quantitation.
CD4+ T cells were negatively selected from PBMC as de-
scribed previously. 15 μl of cellular lysates in NuPAGE LDS
Sample Buffer with 2-mercaptoethanol (equal to 0.6 million
cells) were resolved by NuPAGE 4-12% gel, then transferred
to PVDF membrane. The membrane was blocked by 5%
non-fat dry milk/TBST and incubated with anti-SLFN11
mAb (1:500 dilution, Santa Cruz Biotech SLFN11 Antibody
(E-4): sc-374339) or anti-GAPDH (1:2500, Cell Signal Tech
GAPDH (D16H11) XP® Rabbit mAb #5174) in 5% BSA/
TBST at 4C overnight. The next day, the membrane was
washed and incubated with Cell Signal Tech anti-mouse or
anti-rabbit HRP antibodies respectively and developed with
PerkinElmer Western Lightning ECL Pro. The immunoblot-
ting bands were quantified with ImageJ64 software. The
quantified SLFN11 protein expression levels were normal-
ized to corresponding GAPDH protein levels to ensure
equal loading.
Flow cytometry
Cryopreserved PBMCs were quickly thawed, washed in
FACS buffer (2 mM EDTA, 0.5% BSA in ice-cold PBS) and
surface stained for 30 min at 4°C. Activation panel in-
cluded the following antibodies: CD3-ECD (1:50, UCHT1,
Beckman Coulter), CD4-PacificBlue (1:50, RPA-T4, Beckman
Coulter), CD8-QDot605 (3B5, Invitrogen), CD14-APC/Cy7
(1:100, MΦP9, Becton Dickinson), CD19-APC/Cy7 (1:100,
SJ25C1, BD Pharmingen), CD38-PE (1:50, HB7, BD
Pharmingen), HLA-DR-FITC (1:200, L243 (G46-6), BD
Pharmingen), and a live/dead marker (Invitrogen) emitting
in the aqua wavelength. After staining, the cells were washed
three times, fixed in 2% paraformaldehyde, and events were
collected on a Becton Dickinson LSR-II, using FACS DIVA
software (BD Biosciences). Data were analyzed using
FlowJo software (version 9.3.2, TreeStar). FMOs were car-
ried out for compensation purposes. T cell activation levels
are reported as the percentage of CD4+ T cells co-
expressing HLA-DR and CD38 and the mean fluorescence
intensity (MFI) of HLA-DR.
Statistical analysis
A battery of statistical tests including unpaired t tests
and Pearson’s r correlation coefficient were applied to
data using GraphPad Prism v5.0c.Additional file
Additional file 1: Figure S1. FACS-based sorting of CD4+ T cell
subpopulations. PBMCs were isolated by Ficoll density gradient, stained
with aqua amine reactive dye, and then stained with fluorescently-
conjugated monoclonal antibodies against CD3, CD4, CD45RO, CD27,
CCR7, CD57 and CD14. After gaining on lymphocytes and singlets, and
excluding non-viable cells (using amine reactive dye) and
CD14+ monocytes, CD3+CD4+ cells were sorted as illustrated:
(1) Naïve (CD45RO-CCR7+CD27+CD57-); (2) Central Memory (CD45RO
+CCR7+CD27+); (3) Transitional Memory (CD45RO+CCR7-CD27+); and
(4) Effector Memory (CD45RO+CCR7-CD27-). Table S1. Subject
characteristics. Table S2. P values for inter-disease state gene expression
comparisons.
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